High prevalence of vertebral fractures and low trabecular bone score in patients with fragility fractures: A cross-sectional sub-study of NoFRACT by Borgen, Tove Tveitan et al.




High prevalence of vertebral fractures and low trabecular bone score in
patients with fragility fractures: A cross-sectional sub-study of NoFRACT
Tove T. Borgena,b,⁎, Åshild Bjørneremc,d, Lene B. Solberge, Camilla Andreasenc,f,
Cathrine Brunborgg, May-Britt Stenbroa, Lars M. Hübschleh, Anne Froholdti, Wender Figvedj,
Ellen M. Apalsetk,l, Jan-Erik Gjertsenm,n, Trude Bassoo, Ida Lunde, Ann K. Hansenc,f,
Jens-Meinhard Stutzerp, Cecilie Dahlq, Tone K. Omslandq, Lars Nordslettenb,e, Frede Frihagene,
Erik F. Eriksenb,r
a Department of Rheumatology, Vestre Viken Hospital Trust, Drammen Hospital, Drammen, Norway
bDepartment of Clinical Medicine, University of Oslo, Oslo, Norway
c Department of Clinical Medicine, UiT - The Arctic University of Norway, Tromsø, Norway
dDepartment of Obstetrics and Gynecology, University Hospital of North Norway, Tromsø, Norway
e Division of Orthopedic Surgery, Oslo University Hospital, Oslo, Norway
fDepartment of Orthopedic Surgery, University Hospital of North Norway, Tromsø, Norway
gOslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital, Oslo, Norway
hDepartment of Orthopedic Surgery, Vestre Viken Hospital Trust, Drammen Hospital, Drammen, Norway
iDepartment of Physical Medicine, Vestre Viken Hospital Trust, Drammen Hospital, Drammen, Norway
jDepartment of Orthopedic Surgery, Vestre Viken Hospital Trust, Bærum Hospital, Bærum, Norway
k Bergen group of Epidemiology and Biomarkers in Rheumatic Disease, Department of Rheumatology, Haukeland University Hospital, Bergen, Norway
l Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway
mDepartment of Orthopedic Surgery, Haukeland University Hospital, Bergen, Norway
nDepartment of Clinical Medicine, University of Bergen, Bergen, Norway
o Department of Orthopedic Surgery, St. Olavs University Hospital, Trondheim, Norway
p Department of Orthopedic Surgery, Møre and Romsdal Hospital Trust, Molde Hospital, Molde, Norway
q Department of Community Medicine and Global health, Institute of Health and Society, University of Oslo, Oslo, Norway
r Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway








A B S T R A C T
Purpose: Norway has among the highest incidence rates of fractures in the world. Vertebral fracture assessment
(VFA) and trabecular bone score (TBS) provide information about fracture risk, but their importance have not
been studied in Norwegian patients with fragility fractures. The objectives of this study were to examine the
clinical characteristics of a cohort of women and men with fragility fractures, their prevalence of vertebral
fractures using VFA and prevalence of low TBS, and explore the differences between the sexes and patients with
and without vertebral fractures.
Methods: This cross-sectional sub-study of the Norwegian Capture the Fracture Initiative (NoFRACT) included
839 patients with fragility fractures. Of these, 804 patients had bone mineral density (BMD) of the total hip,
femoral neck and/or spine assessed using dual energy x-ray absorptiometry, 679 underwent concomitant VFA,
771 had TBS calculated and 696 responded to a questionnaire.
Results: Mean age was 65.8 (SD 8.8) years and 80.5% were women. VFA revealed vertebral fractures in 34.8% of
the patients and 34.0% had low TBS (≤ 1.23), with no differences between the sexes. In all patients with valid
measures of both VFA and TBS, 53.8% had either vertebral fractures, low TBS, or both. In the patients with
osteopenia at the femoral neck, 53.6% had either vertebral fractures, low TBS, or both. Femoral neck BMD T-
score≤−2.5 was found in 13.8% of all patients, whereas the corresponding figure was 27.4% using the skeletal
site with lowest T-score. Women exhibited lower BMD at all sites and lower TBS than men (1.27 vs. 1.29), (all
p < 0.05). Patients with prevalent vertebral fractures were older (69.4 vs. 64.0 years), exhibited lower BMD at
all sites and lower TBS (1.25 vs.1.29) than those without vertebral fractures (all p < 0.05). Before assessment,
8.2% were taking anti-osteoporotic drugs (AOD), and after assessment, the prescription rate increased to 56.2%.
Conclusions: More than half of the patients with fragility fractures had vertebral fractures, low TBS or both. The
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prescription of AOD increased seven fold from before assessment to after assessment, emphasizing the im-
portance of risk assessment after a fragility fracture.
1. Introduction
Norway has among the highest rates of hip and forearm fractures in
the world [1,2] and the highest prevalence of vertebral fractures in
Europe [3]. Mortality is high, especially following hip and vertebral
fractures [4,5], as is morbidity, with considerable impact on quality of
life and high health economic costs [6]. Still, secondary fracture pre-
vention in Norway is suboptimal. After a hip fracture, only 15% of
women and 4% of men received treatment with anti-osteoporotic drugs
(AOD) [7]. To meet this challenge, the Norwegian Capture the Fracture
Initiative (NoFRACT) was established to improve secondary fracture
prevention by introducing a Fracture Liaison Service (FLS) model of
care at seven hospitals in Norway [8].
In risk assessment following a fragility fracture, a broad diagnostic
approach is required, because more than half of the patients reveal bone
mineral density (BMD) T-scores in the osteopenic range [9,10]. In-
formation on clinical risk factors is important and additional informa-
tion on bone strength is desirable to make correct treatment decisions.
Vertebral fracture assessment (VFA) and Trabecular bone score (TBS)
calculations are easily accessible approaches when using dual energy x-
ray absorptiometry (DXA). VFA provides information on number and
grade of compression of fractured vertebrae, which is related to future
fracture risk [11]. TBS is a textural index of trabecular bone structure
obtained from anterior-posterior DXA images of the lumbar spine that
predicts fractures independently of BMD in women [12–14] and men
[15]. TBS has been reported to add value beyond BMD for identification
of vertebral fractures in the non-osteoporotic range [16,17]. Studies on
VFA and TBS in Norwegian patients with fragility fractures are, how-
ever, lacking.
The aims of this study were to i) examine the clinical characteristics
of a cohort of Norwegian women and men with fragility fractures, along
with their prevalence of vertebral fractures using VFA and prevalence
of low TBS, and ii) explore the differences in BMD T-score and TBS
between sexes and between patients with and without prevalent ver-
tebral fractures.
2. Materials and methods
2.1. Study subjects
NoFRACT is an ongoing multicenter study in the orthopedic de-
partments at 7 hospitals in Norway and 23,578 patients were enrolled
by Jan 2018 [8]. The objectives are to improve secondary fracture
prevention by introducing a standardized intervention program con-
sisting of an FLS model of care for identification, assessment and
treatment of osteoporosis in patients with fragility fractures. NoFRACT
will investigate the effect of this intervention on the rate of subsequent
fractures. All women and men 50 years and older with a recently di-
agnosed fragility fracture are eligible to the intervention. Those with
fractures of fingers, toes, skull and face are ineligible. The coordinating
nurse identifies patients based on ICD-10 codes and eligibility criteria,
and provides information on the project either in person or in a letter to
in- and outpatients, and information on lifestyle advice, sufficient in-
take of calcium and vitamin D through diet or supplementation and fall
prevention. Blood samples are obtained to rule out common causes for
secondary osteoporosis. Patients are individually evaluated and treated
according to comorbidities and preferences. AOD (mainly alendronate
or zoledronic acid) are offered to patients with hip fracture, vertebral
fracture or 2 or more fragility fractures regardless of BMD T-score or 10-
year probability of major osteoporotic fracture calculated using the
Fracture Risk Assessment Tool (FRAX). Patients with their first fragility
fracture are offered DXA for assessment of BMD T-score of both hips
and spine, and/or FRAX score calculation. Treatment is offered to those
with a BMD T-score ≤−1.5 or FRAX score ≥20%.
Fig. 1. Patients in the Norwegian Capture the Fracture Initiative (NoFRACT) sub-study.
DXA, dual energy x-ray absorptiometry; FRAX, 10-year probability of major osteoporotic fracture calculated using the Fracture Risk Assessment Tool (FRAX).
T.T. Borgen, et al. Bone 122 (2019) 14–21
15
This consent based sub-study (NoFRACTsub: NCT02608801) of
NoFRACT (NoFRACT: NCT02536898) is ongoing at 2 of the 7 hospitals
(Fig. 1). Patients were recruited among those who were referred to DXA
at the University Hospital of North Norway (UNN), Tromsø from 1 Oct
2015 to 31 Dec 2017 (n=844) and the Drammen Hospital in south/
eastern part of Norway from 1 Jan 2016 to 31 Dec 2017 (n= 1838). At
these 2 hospitals, over 90% of the patients with fragility fractures were
identified and offered assessment. Patients with communication pro-
blems, cognitive dysfunction, or short life expectancy, were not eligible
to the sub-study. Some patients were not included due to lack of time or
interest, or difficulties with follow-up. Although DXA was not needed
for treatment decision for those with hip fracture, vertebral fracture or
multiple fractures, we performed DXA in as many as possible, because
baseline values are useful during follow-up.
Of 839 patients (309 in Tromsø and 530 in Drammen), 696 com-
pleted a questionnaire. Of 725/731 patients who had a DXA scan of the
right/left hip, one patient was excluded due to poor imaging quality. Of
785 patients who had an anteroposterior DXA scan of the lumbar spine,
8 patients were excluded due to anatomical aberrations, degenerative
or postoperative changes in three or more vertebrae. VFA was per-
formed in 679 patients. Of 771 patients with TBS calculated, 26 were
excluded due to body mass index (BMI) > 37 kg/m2 and 15 were ex-
cluded due to three or more abnormal lumbar vertebrae. Hence, 724/
730 patients with DXA scans of the right/left hip, 777 with DXA of the
lumbar spine, 679 with VFA and 730 with TBS calculated were included
in the analyses. The proportion of vertebrae that could not be assessed
due to low imaging quality was 8.4%, mainly in the upper thoracic
region (T4–6). A total of 608 patients had both DXA and VFA performed
and also TBS calculated. All patients in this sub-study provided written
informed consent. The study was approved by The Regional Committee
for Medical and Health Research Ethics (REK 2014/2260) and was
conducted in accordance with the World Medical Association
Declaration of Helsinki.
Table 1
Characteristics of all 839 patients with fragility fracture and stratified by sex.
n All Women Men
n (%) 839 839 675 (80.5) 164 (19.5)c
Age (years) 839 65.8 ± 8.8 65.6 ± 8.7 66.7 ± 9.2
Caucasian, n (%) 839 815 (97.0) 655 (96.9) 160 (97.6)
Height (cm) 784 167.1 ± 8.2 164.6 ± 6.2 177.7 ± 6.9c
Weight (kg) 784 75.0 ± 14.8 72.2 ± 13.3 86.9 ± 15.4c
Body mass index
(kg/m2)
784 26.8 ± 4.6 26.7 ± 4.6 27.4 ± 4.1
Index fracture 839
Hip, n (%) 73 (8.7) 49 (7.3) 24 (14.6)b
Forearm, n (%) 309 (36.8) 274 (40.6) 35 (21.3)b
Proximal humerus, n (%) 105 (12.5) 90 (13.3) 15 (9.2)
Vertebral, n (%) 50 (6.0) 40 (5.9) 10 (6.1)
Ankle, n (%) 148 (17.6) 110 (16.3) 38 (23.2)
Other sites, n (%) 154 (18.4) 112 (16.6) 42 (25.6)a
Fractures after age of 50 years 639
1, n (%) 381 (59.6) 302 (57.6) 79 (68.7)a
2, n (%) 160 (25.0) 134 (25.5) 26 (22.6)
≥3, n (%) 98 (15.4) 88 (16.9) 10 (8.7)a
Fractures before index fracture, n (%) 258 (40.4) 222 (42.4) 36 (31.3)a
Prevalent vertebral fractured, n (%) 679 236 (34.8) 190 (34.6) 46 (35.7)
Trabecular Bone Score L1-L4 730 1.27 ± 0.11 1.27 ± 0.10 1.29 ± 0.12a
≥1.31, n (%) 274 (37.5) 215 (36.4) 59 (42.1)
1.23–1.31, n (%) 208 (28.5) 169 (28.7) 39 (27.9)
≤1.23, n (%) 248 (34.0) 206 (34.9) 42 (30.0)
Femoral neck BMD (g/cm2) 730 0.816 ± 0.121 0.805 ± 0.116 0.866 ± 0.130c
Femoral neck T-score −1.6 ± 0.9 −1.7 ± 0.8 −1.2 ± 0.9c
Normal, n (%) 155 (21.2) 103 (17.3) 52 (38.5)c
Osteopenia, n (%) 475 (65.0) 404 (67.8) 71 (52.6)b
Osteoporosis, n (%) 101 (13.8) 89 (14.9) 12 (8.9)
Total hip, BMD (g/cm2) 730 0.865 ± 0.134 0.849 ± 0.126 0.938 ± 0.144c
Total hip T-score −1.1 ± 1.1 −1.3 ± 1.0 −0.5 ± 1.1c
Lumbar spine BMD (g/cm2) 777 1.058 ± 0.184 1.038 ± 0.178 1.145 ± 0.179c
Lumbar spine T-score −1.1± 1.5 −1.3 ± 1.4 −0.4 ± 1.4c
Lowest T-score of all sites 799 −1.9 ± 1.0 −2.0 ± 1.0 −1.5 ± 1.0c
Normal, n (%) 120 (15.0) 76 (11.8) 44 (28.8)c
Osteopenia, n (%) 460 (57.6) 372 (57.6) 88 (57.5)
Osteoporosis, n (%) 219 (27.4) 198 (30.6) 21 (13.7)b
Supplementation before assessment
Vitamin D, n (%) 690 457 (66.2) 378 (67.5) 79 (60.8)
Calcium, n (%) 687 146 (21.3) 129 (23.1) 17 (13.3)a
Prescription of AOD
Before assessment, n (%) 729 60 (8.2) 57 (9.6) 3 (2.2)b
New after assessment, n (%) 737 354 (48.0) 315(52.6) 39 (28.3)c
Total after assessment, n (%) 737 414 (56.2) 372 (62.2) 42 (30.5)c
Values are mean ± SD or n (%). The variation in total numbers was due to some missing data.
BMD, bone mineral density; AOD, anti-osteoporotic drugs.
a p < 0.05.
b p < 0.01.
c p < 0.001 compared to women.
d Prevalent vertebral fracture, included semiquantitative (SQ) score of SQ1, SQ2 and SQ3 fractures.
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2.2. Variables
The index fractures that led to inclusion were hip fractures (femoral
neck, trochanteric and subtrochanteric), forearm fractures, proximal
humerus fractures, vertebral fractures (thoracic- or lumbar spine),
ankle fractures (one, two or both malleoli), and other fractures.
Vertebral fractures that led to inclusion in the study were identified on
x-ray, CT or MRI, not using VFA. The prevalent vertebral fractures in-
cluded only vertebral fractures revealed using VFA.
Information on number and type of fractures after the age of 50,
supplementation of calcium and vitamin D and current use of AOD was
collected through a questionnaire. Information on new prescriptions of
AOD after assessment was obtained from medical records.
Height and weight were measured, and BMI was calculated as
weight (kg) per square meter height. BMD was measured at femoral
neck and total hip at both sides and lumbar spine (L1-L4) using DXA
(GE Lunar, Prodigy Pro, Madison, WI, USA) in Tromsø and iDXA (GE
Lunar, Pro, Madison, WI, USA) in Drammen. Daily phantom Quality
Assurance (QA) of the DXA equipment was performed. Fractured
lumbar vertebrae were excluded. Left hip was used in the calculations
of BMD T-score of femoral neck and total hip. Osteoporosis was defined
as femoral neck BMD T-score≤−2.5, and osteopenia as a femoral neck
BMD T-score between≤−1.0 and− 2.5 according to the World
Health Organization (WHO) DXA-criteria [18], using the Third National
Health and Nutrition Examination Survey reference data [19]. The
proportion of patients with osteoporosis and osteopenia at the site with
the lowest T-score (femoral neck, total hip or lumbar spine), was cal-
culated as recommended by the International Society of Clinical Den-
sitometry (ISCD) [20]. Female reference population was used for men.
Lateral thoracolumbar spine (T4-L4) images were obtained with the
patient in a lateral decubitus position with lumbar support and hips
flexed 90 degrees. VFA of the fracture severity was performed by an
experienced physician (TTB) using the semiquantitative (SQ) vertebral
deformity scoring method by Genant [21]. This combines the visual
examination of deformation of the vertebral body (height loss of the
anterior, middle, posterior or the whole vertebra) and grading of the
vertebrae after proportion of height loss. A SQ score of 0 (SQ0) (< 20%
height loss) was considered as a normal, non-fractured vertebra, SQ1
(20–25% height loss) as a mild fracture, SQ2 (25–40% height loss) as a
moderate fracture, and SQ3 (≥ 40% height loss) as a severe fracture. In
addition, the exact SQ grading of height loss of the fractured vertebrae
was performed morphometrically within Encore with manually six-
point labelling [21]. Deformities identified as Schmorl's or Modic le-
sions, short vertebral height, extensive degenerative changes with de-
formation and physiological wedging of vertebrae were not counted as
fractures. An experienced ISCD certificated clinical technician (MBS),
who was blinded to the initial results, reviewed a random sample of 200
lateral spine images. Spinal deformity index (SDI) was calculated as the
sum of the SQ score of all T4-L4 vertebrae; SQ0=0 points, SQ1=1
point, SQ2=2 points and SQ3=3 points [22].
TBS was calculated from the DXA scans used for lumbar spine BMD
(L1-L4) using TBS iNsight software (Madimaps, Geneva, Switzerland)
version 3.0.1. Fractured vertebrae were excluded. The reference popu-
lation was the European (Medimaps) for both sexes. The TBS values were
divided into three groups, as recommended by Medimaps (TBS insight
user guide TM-001-02), and based on a meta-analysis of fracture risk
assessment as a function of TBS utilizing 14 prospective population-based
cohorts of 17,809 women and men. The estimated fracture risk was: high
TBS≥1.31 (low fracture risk), TBS between 1.23 and 1.31 (intermediate
fracture risk), and low TBS≤1.23 (high fracture risk) [23].
Fig. 2. (A) The number and (B) the proportion, site and grade of compression of fractured vertebrae in women and men. Semi-quantitative (SQ) score 1=mild
fracture, SQ2=moderate fracture, SQ3= severe fracture, for each vertebra from thoracic and lumbar spine (T4 to L4).
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2.3. Statistical analyses
Statistical analyses were performed using Stata (Version 15,
StataCorp LP, TX, USA). Continuous variables were checked for nor-
mality with quantile-quantile (QQ) plots and reported as means with
standard deviation (SD). Differences in means between groups were
calculated using Student's t-test. Categorical variables were reported as
number and percentage. Groups were compared using chi square test in
samples> 100 and Fisher's exact test in smaller samples. The inter-
observer agreement of the assessment of a vertebral fracture (SQ1-SQ3)
was calculated using Cohen's Kappa value (κ) with quadratic weighting.
The inter-observer agreement by grade of severity of the fractures,
within each SQ group, was calculated using Cohen's κ without
weighting. Landis and Koch guidelines were followed to interpret the
levels of agreement by Cohen's κ: almost perfect agreement (κ > 0.81),
substantial agreement (κ=0.61–0.80), moderate agreement
(0.41–0.60), fair agreement (0.21–0.40), slight agreement (0–0.20) and
poor agreement (< 0) [24].
3. Results
3.1. Characteristics of all patients with fractures
In all the 839 patients, the distribution of the index fractures was
8.7% hip, 36.8% forearm, 12.5% proximal humerus, 6.0% vertebral,
17.6% ankle and 18.4% other types (Table 1). A total of 40.4% reported
one or more fractures prior to the index fractures. In those with VFA,
34.8% had prevalent vertebral fractures. Mean TBS was 1.27, and
34.0% had low TBS. Osteoporosis was present at the femoral neck in
13.8% of the patients and in 27.4% at the site with lowest BMD T-score.
Osteopenia was present at the femoral neck in 65.0% of the patients and
in 57.6% at the site with lowest BMD T-score. Only 8.2% used AOD
before assessment, 48.0% had a new prescription after assessment, thus
a total of 56.2% had AOD prescribed after assessment.
3.2. Comparison of women and men
A total of 80.5% were women. Mean age did not differ between the
sexes. Women exhibited a smaller proportion of hip fractures than men
(7.3% vs. 14.6%, p=0.005), but a larger proportion of forearm frac-
tures (40.6% vs. 21.3%, p= 0.001). A larger proportion of women than
men had sustained fractures before participating in the study (42.4% vs.
31.3%, p= 0.036). A higher number of women than men had vertebral
fractures (190 vs. 46), but there was no difference in prevalence of
vertebral fractures between sexes (34.6% vs. 35.7%, p=0.837)
(Table 1). Vertebral fractures were most prevalent at T7, T11 and T12
(Fig. 2). Mean TBS of L1-L4 was lower in women than men (1.27 vs.
1.29, p= 0.044), but the proportion with low TBS did not differ be-
tween the sexes. Mean BMD T-score of femoral neck, total hip, lumbar
spine and lowest T-score of any site was lower in women than in men
(all p < 0.001). A higher proportion of women than men had osteo-
porosis at the site with lowest T-score (30.6% vs. 13.7%, p= 0.008).
More women than men had AOD prescribed before assessment (9.6%
vs. 2.2%) and after assessment (62.2% vs. 30.5%), (both p < 0.01).
3.3. Comparison of patients with and without prevalent vertebral fractures
Patients with vertebral fractures were older (69.4 vs. 64.0 years),
shorter (166.2 vs. 167.7 cm) and a larger proportion reported previous
fractures compared to those without vertebral fractures (all p < 0.05,
Table 2). Patients with vertebral fractures had lower mean TBS (1.25 vs.
1.29) and a larger proportion had low TBS (42.9% vs. 29.1%, both
p < 0.001) than those without vertebral fractures. BMD at all sites
were lower, and a higher proportion had osteoporosis at the femoral
neck (16.9% vs. 9.5%) and at the site with lowest T-score (37.0% vs.
22.7%, all p < 0.05) in those with than without vertebral fractures. A
larger proportion of patients with vertebral fractures on VFA had AOD
prescribed after assessment (70.0% vs. 47.8%, p < 0.001).
3.4. Prevalence of vertebral fractures and low TBS
Of all 608 patients with BMD, VFA and TBS assessed, 53.8% had either
vertebral fracture, low TBS, or both (Fig. 3A). Only 13.2% of them had
osteoporosis at the femoral neck. Of 394 with osteopenia at the femoral
neck, 53.6% had either vertebral fracture, low TBS or both (Fig. 3B).
Table 2
Comparison of characteristics in patients with and without vertebral fractures





Women, n (%) 679 190 (80.5) 360 (81.3)
Age (years) 679 69.4 ± 7.9 64.0 ± 8.4c
Height (cm) 663 166.2 ± 8.0 167.7 ± 8.0a
Weight (kg) 663 73.5 ± 14.3 75.3 ± 15.0
Body mass index (kg/
m2)
663 26.5 ± 4.2 26.7 ± 4.6
Index fracture 679
Hip, n (%) 21 (8.9) 29 (6.6)
Forearm, n (%) 73 (30.9) 197 (44.5)b
Proximal humerus, n
(%)
31 (13.1) 48 (10.8)
Vertebral, n (%) 34 (14.4) 5 (1.1)c
Ankle, n (%) 33 (14.0) 90 (20.3)a
Other sites, n (%) 44 (18.7) 74 (16.7)
Fractures after age of
50 years
526
1, n (%) 308 80 (43.5) 228 (66.7)c
2, n (%) 137 60 (32.6) 77 (22.5)a
≥3, n (%) 81 44 (23.9) 37 (10.8)c
Trabecular Bone Score
L1-L4 (SD)
625 1.25 ± 0.10 1.29 ± 0.10c
≥1.31, n (%) 63 (29.7) 172 (41.6)b
1.23–1.31, n (%) 58 (27.4) 121 (29.3)
≤1.23, n (%) 91 (42.9) 120 (29.1)b
Femoral neck BMD (g/
cm2)
635 0.786 ± 0.115 0.830 ± 0.116c
Femoral neck T-score −1.8 ± 0.8 −1.5 ± 0.8c
Normal, n (%) 65 (27.5) 126 (28.4)
Osteopenia, n (%) 131 (55.5) 275 (62.1)
Osteoporosis, n (%) 40 (16.9) 42 (9.5)b
Total hip BMD (g/cm2) 0.831 ± 0.135 0.881 ± 0.129c
Total hip T-score −1.4 ± 1.1 −1.0 ± 1.0c
Lumbar spine BMD (g/
cm2)
656 1.023 ± 0.181 1.076 ± 0.179c
Lumbar spine T-score −1.4 ± 1.4 −1.0 ± 1.4c
Lowest T-score of all
sites
670 −2.1 ± 1.0 −1.8 ± 1.0c
Normal, n (%) 23 (10.0) 72 (16.4)a
Osteopenia, n (%) 122 (53.0) 268 (60.9)
Osteoporosis, n (%) 85 (37.0) 100 (22.7)c
Supplementation before
assessment
Vitamin D, n (%) 559 137 (70.6) 238 (65.2)




602 19 (9.3) 24 (6.0)
New after assessment,
n (%)
606 125 (60.7) 167 (41.8)c
Total after assessment,
n (%)
144 (70.0) 191 (47.8)c
Values are mean ± SD or n (%). The variation in total numbers was due to
some missing data.
BMD, bone mineral density; AOD, anti-osteoporotic drugs.
a p < 0.05.
b p < 0.01.
c p < 0.001 compared to those with vertebral fracture.
d Vertebral fracture, included semiquantitative (SQ) score of SQ1, SQ2 and
SQ3 fractures.
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Of a total of 8827 imaged vertebrae, 8.4% were excluded because of
insufficient image quality (Table 3). Of the evaluable vertebrae 5% had
a fracture, 44.7, 37.8 and 17.5% were SQ1, SQ2 and SQ3 fracture, re-
spectively. A total of 34.8% of the patients had a SQ1, SQ2 or SQ3
fracture, while after exclusion of SQ1 fractures, 20.3% had a SQ2 or
SQ3 fracture. The prevalence of vertebral fracture or SDI did not differ
between sexes. The inter-observer agreement of SQ1-SQ3 fractures was
almost perfect with a κ of 0.84 (95% CI: 0.70, 0.98). Inter-observer
agreement of SQ1 and SQ2 fractures was moderate with a κ of 0.48
(95% CI: 0.34, 0.61) and 0.55 (95% CI: 0.41, 0.69), respectively. Inter-
observer agreement of SQ3 fractures could only be calculated at T8, T9
and L2 due to few observations with a κ of 0.66 (95% CI: 0.53, 0.80).
4. Discussion
In this cohort of Norwegian patients with fragility fractures, one in
three had vertebral fractures on VFA, one in three had low TBS, and
more than half of the patients had either vertebral fractures, low TBS or
both. The majority of the patients had osteopenia. A small proportion
had osteoporosis at the femoral neck, but this proportion was larger
when using the site with lowest BMD T-score. Women had lower BMD
and TBS than men. Patients with vertebral fractures were older and had
lower BMD and TBS than those without vertebral fractures. The pre-
scription of AOD increased 7 fold, and about half of the patients were
prescribed AOD after the assessment, more women than men, and more
patients with than without vertebral fractures.
We found higher prevalence of vertebral fractures of 35% compared
to a FLS cohort in Scotland where 19–20% of women and men of
50 years and older with non-vertebral fractures had a vertebral fracture
[25]. The prevalence of vertebral fracture was 37% in another FLS
cohort of women and men in France, which was similar to our findings
[16]. However, those patients were older than in our cohort (age of 74
Fig. 3. Proportion of (A) all fracture patients with dual energy x-ray absorptiometry (DXA), vertebral fracture assessment (VFA) and trabecular bone score (TBS)
(n=608) who had vertebral fractures, low TBS, or both, and osteoporosis of the femoral neck, and B) fracture patients with osteopenia of the femoral neck (n=394)
with vertebral fracture, low TBS, or both.
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vs. 66 years), and a higher proportion had hip fracture (51 vs. 9%) [16].
In population-based studies, the prevalence of vertebral fracture was
19–20% in women and men over 70 years in Norway [26] and 16–19%
in the European Vertebral Osteoporosis Study, with the highest rates in
the Scandinavian countries [3]. As a prior fracture, non-vertebral and
vertebral, increases the risk for a subsequent fracture, fracture cohorts
have higher prevalence of vertebral fracture than do the general po-
pulation as shown in population-based studies, and they have more co-
morbidity [3,16,25,26]. Although a higher number of women than men
had a vertebral fracture we found no difference between sexes in pre-
valence of vertebral fractures in percentage terms. Despite of the dif-
ferences in prevalence of vertebral fracture between studies; the pre-
valence tended to be similar in both sexes within each study.
Identifying those with vertebral fractures is challenging because few
of them come to the hospital for an x-ray or other examination [27].
The large proportion of vertebral fractures in this fracture cohort is
interesting because vertebral fractures increase the risk of new fracture
up to five fold [28,29]. Of all fractured vertebrae in our study, 45%
were mild fractures (SQ1) compared to 5% in a general population
[26]. One reason for the identification of so many SQ1 fractures may be
that the images were obtained using new DXA machines with good
image quality, particularly the iDXA. There have been some discussions
regarding the SQ1 fractures, whether the majority are not true osteo-
porotic fractures. However, we carefully checked that physiological
wedging and other deformities were not misclassified as a SQ1 fracture.
Other methods may capture better the small fractures, even fractures
with less height loss than 20%. After we excluded the SQ1 fractures, the
prevalence of vertebral fractures (SQ2 and SQ3) was 20% in women
and 18% in men, which is similar to the findings in the fracture cohort
from Scotland [25].
Another interesting finding was the seven fold increased AOD pre-
scription (from 8% before to 56% after the assessment). This is in
agreement with other studies that have introduced FLS where an in-
crease in AOD prescription from 5‐19% before assessment to 51–73%
after assessment is described [30,31], and that illuminates the treat-
ment gap and importance of assessing patients after a fragility fracture.
We used treatment criteria based upon fracture (hip, vertebral, 2 or
more fragility fractures), reduction in BMD T-score≤−1.5 and/or
high FRAX score≥ 20%, which contributed to the high AOD prescrip-
tion rate in this study. TBS was not included among the criteria we used
for treatment initiation. ISCD does not support use of TBS alone for
treatment decision making and recommends that the TBS-adjusted
FRAX score should be used. A large proportion had low TBS and ver-
tebral fracture in our fracture cohort as shown in Fig. 3. This may be
due to the cross-sectional design of the study that included only patients
with fractures and no fracture-free controls.
To our knowledge, this is the first Scandinavian study on patients
with fragility fractures described with both VFA and TBS, in addition to
clinical risk factors and BMD. However, our study has some limitations.
Only patients in need of a DXA examination and who were healthy
enough to undergo follow-up were invited to this sub-study. This re-
sulted in a healthy selection bias with a relatively small proportion of
hip fractures in this sub-study. Without this bias, we could have had a
higher proportion of patients with osteoporosis, vertebral fractures and
low TBS. Although we tried to avoid observation bias, the two centers
differed at some points. The Prodigy Pro DXA scanner in Tromsø had
lower resolution and quality of the lateral spine images, and thus more
non-evaluable vertebrae, compared to images obtained using the iDXA
Pro in Drammen. However, none of the lateral images had too low
quality for VFA, so all images were evaluated. The same experienced
physician performed all the VFA, and the inter-observer agreement of
the assessment of vertebral fractures was almost perfect. This is in
agreement with prior studies that have reported small inter-observer
variation [21].
In conclusion, vertebral fractures, low TBS, or both were present in
more than half of women and men who were assessed after a fragility
fracture. The prescription of AOD increased seven fold from before to
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Table 3
Vertebral fracture assessment of 8827 vertebrae in 679 patients.
Total Women Men
Patients, n (%) 679 550 (81.0) 129 (19.0)
Imaged vertebrae, n (%) 8827 7150 1677
Excluded vertebrae, n (%) 742 (8.4) 600 (8.4) 142 (8.5)
Evaluable vertebrae, n (%) 8085
(91.6)
6550 (91.6) 1535 (91.5)




6222 (95.0) 1456 (94.9)
Vertebras with fracture 407 (5.0) 328 (5.0) 79 (5.1)
SQ1 deformity, n (%) 182 (44.7) 139 (42.4) 43 (54.4)
SQ2 deformity, n (%) 154 (37.8) 128 (39.0) 26 (32.9)
SQ3 deformity, n (%) 71 (17.5) 61 (18.6) 10 (12.7)
Patients with vertebral fracture
SQ0, with no fractured vertebra, n (%) 443 (65.2) 360 (65.4) 83 (64.3)
SQ1 mild fractures, n (%) 145 (21.4) 114 (20.7) 31 (24.0)
SQ2 moderate fractures, n (%) 113 (16.6) 93 (16.9) 20 (15.5)
SQ3 severe fractures, n (%) 49 (7.2) 39 (7.1) 10 (7.8)
SQ1-SQ3 fractures, n (%) 236 (34.8) 190 (34.6) 46 (35.7)
SQ2-SQ3 fractures, n (%) 138 (20.3) 115 (20.1) 23 (17.8)
Spinal deformity index
0, n (%) 443 (65.2) 360 (65.4) 83 (64.3)
1, n (%) 80 (11.8) 63 (11.5) 17 (13.2)
2, n (%) 63 (9.3) 53 (9.6) 10 (7.8)
3, n (%) 38 (5.6) 31 (5.6) 7 (5.4)
≥4, n (%) 55 (8.1) 43 (7.8) 12 (9.3)
SQ, semiquantitative score.
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